Rueda-Dominguez, AntonioCirauqui, BeatrizGarcia-Castaño, AlmudenaAlvarez-Cabellos, RuthCarral-Maseda, AlbertoCastelo-Fernandez, BeatrizIglesias-Rey, LeticiaRubio-Casadevall, JordiArrazubi, VirginiaMesia, Ricard2023-05-032023-05-032022-03-18Rueda Domínguez A, Cirauqui B, García Castaño A, Alvarez Cabellos R, Carral Maseda A, Castelo Fernández B, et al. SEOM-TTCC clinical guideline in nasopharynx cancer (2021). Clin Transl Oncol. 2022 Apr;24(4):670-680http://hdl.handle.net/10668/21108Nasopharyngeal carcinoma (NPC) is distinct from other cancers of the head and neck in biology, epidemiology, histology, natural history, and response to treatment. Radiotherapy (RT) is the cornerstone of locoregional treatment of non-disseminated disease and the association of chemotherapy improves the rates of survival. In the case of metastatic disease stages, treatment requires platinum/gemcitabine-based chemotherapy and patients may achieve a long survival time.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Clinical Practice GuidelinesDiagnosisFollow-upNasopharyngeal cancerTreatmentHumansNasopharyngeal CarcinomaNasopharyngeal Neoplasmsresearch article35303267open accessQuimioterapiaGemcitabinaCarcinoma NasofaríngeoEpidemiologíaRadioterapiaHistología10.1007/s12094-022-02814-x1699-3055PMC8986714https://link.springer.com/content/pdf/10.1007/s12094-022-02814-x.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986714/pdf